» Articles » PMID: 34572640

Antibiotic Resistance Prevalence and Trends in Patients Infected with in the Period 2013-2020: Results of the European Registry on Management (Hp-EuReg)

Abstract

Bacterial antibiotic resistance changes over time depending on multiple factors; therefore, it is essential to monitor the susceptibility trends to reduce the resistance impact on the effectiveness of various treatments. To conduct a time-trend analysis of resistance to antibiotics in Europe. The international prospective European Registry on Management (Hp-EuReg) collected data on all infected adult patients diagnosed with culture and antimicrobial susceptibility testing positive results that were registered at AEG-REDCap e-CRF until December 2020. : Overall, 41,562 patients were included in the Hp-EuReg. Culture and antimicrobial susceptibility testing were performed on gastric biopsies of 3974 (9.5%) patients, of whom 2852 (7%) were naive cases included for analysis. The number of positive cultures decreased by 35% from the period 2013-2016 to 2017-2020. Concerning naïve patients, no antibiotic resistance was found in 48% of the cases. The most frequent resistances were reported against metronidazole (30%), clarithromycin (25%), and levofloxacin (20%), whereas resistances to tetracycline and amoxicillin were below 1%. Dual and triple resistances were found in 13% and 6% of the cases, respectively. A decrease ( < 0.001) in the metronidazole resistance rate was observed between the 2013-2016 (33%) and 2017-2020 (24%) periods. : Culture and antimicrobial susceptibility testing for are scarcely performed (<10%) in Europe. In naïve patients, resistance to clarithromycin remained above 15% throughout the period 2013-2020 and resistance to levofloxacin, as well as dual or triple resistances, were high. A progressive decrease in metronidazole resistance was observed.

Citing Articles

resistance in Hainan Province, China: investigating phenotypes and genotypes through whole-genome sequencing.

Lv Y, Li D, Zhang D, Chen S, Chen R, Wang Y Front Cell Infect Microbiol. 2025; 14:1505166.

PMID: 39742338 PMC: 11685075. DOI: 10.3389/fcimb.2024.1505166.


: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.

Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A Diseases. 2024; 12(12.

PMID: 39727641 PMC: 11727528. DOI: 10.3390/diseases12120311.


Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.

Alhijazien S, Daoud S, Alzayadi M, Al Sarhan M, Aldomi M, Al Shawabkeh T Cureus. 2024; 16(10):e72033.

PMID: 39569309 PMC: 11578150. DOI: 10.7759/cureus.72033.


Genetic Determinants of Clarithromycin and Fluoroquinolones Resistance in in Serbia.

Kekic D, Jovicevic M, Kabic J, Lolic I, Gajic I, Stojkovic S Antibiotics (Basel). 2024; 13(10).

PMID: 39452199 PMC: 11505191. DOI: 10.3390/antibiotics13100933.


Clarithromycin sustained-release tablet may be an improper therapy for the eradication of .

Zuo X, Shen Q, Luo J, Wang Y, Zhao C Therap Adv Gastroenterol. 2024; 17:17562848241275332.

PMID: 39290332 PMC: 11406650. DOI: 10.1177/17562848241275332.


References
1.
Van Boeckel T, Gandra S, Ashok A, Caudron Q, Grenfell B, Levin S . Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014; 14(8):742-750. DOI: 10.1016/S1473-3099(14)70780-7. View

2.
Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang T, Hoebeke M . resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021; 70(10):1815-1822. DOI: 10.1136/gutjnl-2021-324032. View

3.
Gisbert J, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X . IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2016; 39(10):697-721. DOI: 10.1016/j.gastrohep.2016.05.003. View

4.
Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino I, Ricci C . Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther. 2018; 47(9):1261-1269. DOI: 10.1111/apt.14597. View

5.
Leitsch D . A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology. 2017; 146(9):1167-1178. DOI: 10.1017/S0031182017002025. View